Edition:
United States

DiaSorin SpA (DIAS.MI)

DIAS.MI on Milan Stock Exchange

75.80EUR
15 Dec 2017
Change (% chg)

€-0.60 (-0.79%)
Prev Close
€76.40
Open
€76.00
Day's High
€76.50
Day's Low
€75.45
Volume
98,841
Avg. Vol
80,456
52-wk High
€82.10
52-wk Low
€51.85

Select another date:

Tue, Dec 12 2017

BRIEF-Diasorin Receives CE Mark For A New Bordetella Molecular Diagnostic Test

* RECEIVES CE MARK FOR A NEW BORDETELLA MOLECULAR DIAGNOSTIC TEST Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-DiaSorin Q3 net profit up at EUR 29.3‍​ mln, confirms 2017 guidance

* Q3 NET REVENUE EUR ‍​149.4 MILLION VERSUS EUR 147.0 MILLION YEAR AGO

BRIEF-Diasorin revises its FY 2019 guidance

* INCREASES ITS 2019 REVENUE GUIDANCE TO ABOUT EUR 775 MILLION FROM EUR 735 MILLION

BRIEF-DiaSorin ‍completes acquisition of Elisa immunodiagnostic business portfolio​

* ‍COMPLETES ACQUISITION OF ELISA IMMUNODIAGNOSTIC BUSINESS PORTFOLIO AND ASSOCIATED ASSETS FROM SIEMENS HEALTHINEERS​ Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-DiaSorin ‍earns CE-mark extending sample claims for its Simplexa HSV 1&2 kit​

* ‍EARNS CE-MARK EXTENDING SAMPLE CLAIMS FOR DIASORIN MOLECULAR'S SIMPLEXA HSV 1 & 2 KIT​

BRIEF-DiaSorin Q2 net profit up at EUR 33.6 mln

* Q2 NET PROFIT EUR 33.6 MILLION VERSUS EUR 29.4 MILLION YEAR AGO

BRIEF-DiaSorin launches three primer pairs for use in molecular testing

* LAUNCHES 3 PRIMER PAIRS FOR USE IN MOLECULAR TESTING: PNEUMOCYSTIS JIROVECII, GROUP C STREPTOCOCCUS, AND GROUP G STREPTOCOCCUS Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Diasorin to acquire ELISA immunodiagnostic business portfolio from Siemens Healthineers

* TO ACQUIRE ELISA IMMUNODIAGNOSTIC BUSINESS PORTFOLIO AND ASSOCIATED ASSETS FROM SIEMENS HEALTHINEERS

BRIEF-DiaSorin launches test Iam CBFB-MYH11 for acute myeloid leukemia

* LAUNCHES MOLECULAR DIAGNOSTIC TEST IAM CBFB-MYH11 (AVAILABLE WORLDWIDE EXCEPT UNITED STATES) FOR DIAGNOSIS OF ONE OF THE GENETIC CAUSES OF ACUTE MYELOID LEUKEMIA Source text: http://reut.rs/2tZeE1p Further company coverage: (Gdynia Newsroom)

BRIEF-Diasorin presents its 2017-2019 industrial plan

* DIASORIN WILL CONTINUE TO LOOK FOR POTENTIAL ACQUISITIONS, FOCUSING ON TARGET THAT WILL ALLOW GROUP TO EXPAND ITS CUSTOMER BASE AND ITS PRESENCE IN STRATEGIC MARKETS

Select another date: